Skip to content
Biotechnology, Research Development

Taiwanese enterprises helping to make Australian health and wellbeing innovations a reality

Palin Communications 2 mins read

Call continues for Australian submissions to "Go Healthy with Taiwan"

8 July 2025: The Taiwan Trade Centre in Sydney is continuing to encourage Australian health innovators, companies, entrepreneurs and researchers to make submissions to its "Go Healthy with Taiwan" campaign.

The deadline for submissions is August 14, with six finalists being flown to Taiwan to present their proposals and three winners receiving a prize of $USD30,000 each.

"Go Healthy with Taiwan" is a global initiative that engages institutions, enterprises, researchers and entrepreneurs from around the world to submit innovative proposals that integrate Taiwan’s high-quality health products and holistic solutions. The objective is to fund projects that jointly improve global health standards and promote well-being in cities, communities and business environments across the globe.

Dr Christian Criado-Perez, who is a Research and Insights Associate at the UNSW Business Insights Institute, is encouraging academics in the University of NSW Business School to consider the program.

"Our Institute has made a conscious effort to place a lot more of our energy and focus on building relationships with external partners and to focus on work with social impact. So Go Healthy with Taiwan is a perfect example of the kind of activity that we as a Business School want to get involved in,” said Dr Criado-Perez Chanin.

According to Mr David Cheng-Wei Wu, Director-General of the Taipei Economic and Cultural Office in Sydney, Australia is a very important partner to Taiwan. "We hope that through this program we can source ideas from both Taiwan and Australia, so we can work together to make the ecosystem of healthcare better in the future."

People and organisations with ideas that would benefit from the inclusion of a Taiwanese partner are encouraged to visit the website, identify a Taiwanese enterprise that fits their idea, make a submission and then be in the running for the prizes and the trips to Taiwan. 

For more information on Taiwanese partners and how to submit a proposal for “Go Healthy with Taiwan”, visit https://gohealthy.taiwanexcellence.org/about.html

 


Contact details:

Roberta Sowden

Palin Communications

[email protected]

Luana Lima

Palin Communications

[email protected]

 

Media

More from this category

  • Biotechnology
  • 12/12/2025
  • 11:40
4DMedical Limited (ASX:4DX)

4DMedical secures $30.2 million with options underwrite

Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options• Additional funding results in a proforma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a transformational year Melbourne, Australia, 12 December 2025: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) today announces it has entered into an option underwriting agreement (Underwriting Agreement) with Bell Potter Securities Limited (Underwriter) to fully underwrite the exercise of the 4DXO listed options on issue,…

  • Biotechnology
  • 12/12/2025
  • 10:58
EBR Systems, Inc. (ASX:EBR)

First implant in the Totally Leadless CRT (TLC-AU) Study

Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR evaluates WiSE as a potential first-line therapy for treating newly diagnosed heart failure patients • TLC-AU could meaningfully expand EBR’s addressable market Sunnyvale, California; 12 December 2025: EBR Systems, Inc., developer of the world’s only wireless cardiac pacing device for heart failure, announces the first…

  • Biotechnology
  • 10/12/2025
  • 10:19
OncoSil Medical Limited (ASX:OSL)

First OncoSil treatment in United Kingdom

Sydney, Australia – 10 December 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the first commercial patient treatment in the UK using the OncoSil™ device. The successful treatment was performed on 9 December 2025 at Southampton General Hospital (University Hospital SouthamptonNHS Foundation Trust), a recognised centre of excellence in oncology. Following the hospital’s participation in the TRIPP-FFX clinical study, this significant milestone marks the transition from clinical trial involvement to the commencement of OncoSil’s commercial operations…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.